Real-time continuous glucose monitoring (rt-CGM) technology has much improved over the last few years, becoming more accurate and easier to use. Higher % of Time In glucose Range (TIR) and lower % of Time Below glucose Range (TBR) can be seen when rt-CGM is compared with intermittent scanning continuous glucose monitoring (is-CGM, a.k.a. Flash Glucose Monitoring) or when rt-CGM is combined with open-loop pump therapy (Sensor-Assisted Pump [SAP] therapy) or multiple daily injections (MDI). Integrating rt-CGM in more recent Automated Insulin Delivery (AID) systems (i.e. [advanced] Hybrid Closed-Loop [aHCL] systems) leads to even more optimal TIR and TBR values. This sensor technology has also been shown to benefit diabetes-related quality of life (QoL), although most existing studies have been either qualitative or quantitative and have not assessed if rt-CGM was used in the SAP or in the AID setting. In the Netherlands rt-CGM reimbursement is limited to certain categories of people with type 1 diabetes (PWDs), which has sparked a societal debate. This study, co-authored by Per Winterdijk, Henk-Jan Aanstoot and Giesje Nefs of Diabeter, aimed to get a detailed overview (quantitative and qualitative) of both positive and negative experiences of Dutch PWDs who are using rt-CGM technology and its impact on QoL.
In this cross-sectional, observational study ~8,000−10,000 eligible Dutch PWDs aged ≥18 years currently using rt-CGM were contacted via care and advocacy organizations: Bas van de Goor Foundation, Diabeter, Diabetes+, Diabetesvereniging Nederland, Dutch Diabetes Research Foundation, Sensorvergoeding.nl, Stichting DON, Stichting ééndiabetes, and Stichting JDRF Nederland. They received a link to the information folder, consent form and anonymous survey.
Concluding, the authors state